Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients
Background and Objectives
Minimally invasive surgery for adrenocortical carcinoma (ACC) is controversial. We sought to evaluate the perioperative and long-term outcomes following minimally invasive (MIS) and open resection (OA) of ACC in patients treated with curative intent surgery.
Retrospective data from patients who underwent adrenalectomy for primary ACC at 13 tertiary care cancer centers were analyzed, including demographics, clinicopathological, and operative outcomes. Outcomes following MIS were compared to OA.
A total of 201 patients were evaluated including 47 MIS and 154 OA. There was no difference in utilization of MIS approach among institutions (p = 0.24) or 30-day morbidity (29.3 %, MIS, vs. 30.9 %, OA; p = 0.839). The only preoperatively determined predictor for MIS was smaller tumor size (p < 0.001). There was no difference in rates of intraoperative tumor rupture (p = 0.612) or R0 resection (p = 0.953). Only EBL (p = 0.038) and T stage (p = 0.045) were independent prognostic indicators of overall survival after adjusting for significant factors. The surgical approach was not associated with overall or disease-free survival.
MIS adrenalectomy may be utilized for preoperatively determined ACC ≤ 10.0 cm; however, OA should be utilized for adrenal masses with either preoperative or intraoperative evidence of local invasion or enlarged lymph nodes, regardless of size.
KeywordsAdrenocortical carcinoma Minimally invasive surgery Survival Disease-free survival Surgical approach
Each author listed in the following manuscript contributed significantly to the concept and/or design of this work in the form of data acquisition, analysis, and interpretation of results. Each author was involved in the drafting or revision of the intellectual content included in this manuscript and provided final approval of the current version. All authors agree to be accountable for the following work.
Compliance with Ethical Standards
Disclosures and Funding Sources
- 20.Jin LX, Sanford DE, Squires MH, 3rd, et al.: Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Ann Surg Oncol 2016.Google Scholar